Literature DB >> 15477712

Gastrinomas: advances in diagnosis and management.

Robert T Jensen1.   

Abstract

Gastrinomas causing Zollinger-Ellison syndrome (ZES) are the most common functional, malignant pancreatic endocrine tumors. In this paper, the diagnosis and treatment of these tumors are reviewed, incorporating recent advances in each area. Furthermore, recent advances in their pathology, molecular pathogenesis, and aspects of their localization using somatostatin receptor scintigraphy, as well as their treatment are discussed. Recent data from our NIH prospective studies on patients with ZES are included to illustrate many of these points.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477712     DOI: 10.1159/000080736

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  6 in total

1.  Pathogenesis of gastrinomas associated with multiple endocrine neoplasia type 1.

Authors:  D M Pritchard
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

2.  [Rare occurrence of fulminant acid burn of the esophagus].

Authors:  C Knebel; R Bumm; K Becker; M Burian; J R Siewert
Journal:  Chirurg       Date:  2008-08       Impact factor: 0.955

3.  Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors.

Authors:  Matthias Banasch; Frank Schmitz
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 4.  Medical treatment of gastrinomas.

Authors:  Christoph J Auernhammer; Burkhard Göke
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 5.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

Review 6.  Imaging of gastrinomas by nuclear medicine methods.

Authors:  Martin Béhé; Martin Gotthardt; Thomas M Behr
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 2.275

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.